Previous close | 58.08 |
Open | 57.72 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 57.72 - 58.35 |
52-week range | 34.19 - 66.00 |
Volume | |
Avg. volume | 76,006 |
Market cap | 41.878B |
Beta (5Y monthly) | 0.64 |
PE ratio (TTM) | 59.26 |
EPS (TTM) | 0.98 |
Earnings date | 25 Jul 2024 |
Forward dividend & yield | 0.44 (0.76%) |
Ex-dividend date | 15 May 2024 |
1y target est | 66.20 |
Despite a net loss, MRVI showcases strategic expansions and robust partnerships, setting the stage for future growth.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
Lonza Group ( VTX:LONN ) Full Year 2023 Results Key Financial Results Revenue: CHF6.72b (up 7.9% from FY 2022). Net...